2024
VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model
Boisserand L, Geraldo L, Bouchart J, Kamouh M, Lee S, Sanganahalli B, Spajer M, Zhang S, Lee S, Parent M, Xue Y, Skarica M, Yin X, Guegan J, Boyé K, Leser F, Jacob L, Poulet M, Li M, Liu X, Velazquez S, Singhabahu R, Robinson M, Askenase M, Osherov A, Sestan N, Zhou J, Alitalo K, Song E, Eichmann A, Sansing L, Benveniste H, Hyder F, Thomas J. VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model. Journal Of Experimental Medicine 2024, 221: e20221983. PMID: 38442272, PMCID: PMC10913814, DOI: 10.1084/jem.20221983.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor-CDeep cervical lymph nodesCentral nervous systemEffect of vascular endothelial growth factor-CMeningeal lymphatic vesselsAmeliorated motor performanceCervical lymph nodesIschemic strokeVEGF-C overexpressionIncreased BDNF signalingAcute ischemic strokeBrain cellsIncreased CSF drainageIschemic stroke outcomesModel of ischemic strokeMouse model of ischemic strokeImmune surveillanceCSF drainageLymph nodesFluid drainageNucleus RNA sequencingLymphatic growthLymphatic drainageMouse modelBDNF signaling
2023
Fluorescent liposomal nanocarriers for targeted drug delivery in ischemic stroke therapy
Arul M, Alahmadi I, Turro D, Ruikar A, Abdulmalik S, Williams J, Sanganahalli B, Liang B, Verma R, Kumbar S. Fluorescent liposomal nanocarriers for targeted drug delivery in ischemic stroke therapy. Biomaterials Science 2023, 11: 7856-7866. PMID: 37902365, PMCID: PMC10697427, DOI: 10.1039/d3bm00951c.Peer-Reviewed Original ResearchConceptsSurgical clot removalPEGylated liposomal formulationPreclinical mouse modelsShorter treatment durationPurinergic receptor P2X4Reduced infarct volumeAcute CNS injuryCNS infiltrationLong-term disabilitySystemic deliveryTreatment optionsLiposomal formulationIschemic stroke therapyVulnerable brain regionsAdministered 4Clot removalInfarct volumeLow dosesTreatment durationMouse modelNeuroprotective therapiesCNS injuryLiposomal nanocarriersStroke therapyIschemic stroke
2016
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma
Pirazzoli V, Ayeni D, Meador CB, Sanganahalli BG, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma. Clinical Cancer Research 2016, 22: 426-435. PMID: 26341921, PMCID: PMC4715986, DOI: 10.1158/1078-0432.ccr-15-0620.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAfatinibAnimalsCell Line, TumorCetuximabDrug Evaluation, PreclinicalDrug Resistance, NeoplasmDrug Therapy, CombinationErbB ReceptorsErlotinib HydrochlorideLung NeoplasmsMiceMice, NudeMutationNeoplasm Recurrence, LocalProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins p21(ras)QuinazolinesConceptsTyrosine kinase inhibitorsLung adenocarcinomaLung cancerMouse modelAdvanced EGFR-mutant lung adenocarcinomaFirst-generation tyrosine kinase inhibitorSingle-agent tyrosine kinase inhibitorsEGFR-mutant lung cancerEGFR-mutant lung adenocarcinomaEGFR tyrosine kinase inhibitorsCetuximab-resistant tumorsPotential of afatinibFirst-line therapyMutant lung cancerEGFR antibody cetuximabCombination of afatinibEGFR-TKI afatinibClinical trial developmentEffective treatment strategiesDrug-resistant tumorsAgent erlotinibTKI-naïveAfatinib treatmentTumor escapeClinical trials